English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

ABS TRACT Ob jec ti ve: Do ce ta xel has be co me the stan dard of ca re for hor mo ne-ref rac tory pros ta te can cer (HRPC), ho we ver drug re sis tan ce and to xi city are still chal len ging in da ily can cer practi ce. The an ti-apop to tic path way cen te red aro und the Bcl-2 pro te in might be one of the res pon sib le path ways. Ad ding a se cond drug to do ce ta xel tre at ment is one of the most com mon ap pro ac hes to sol ve this prob lem. Goss ypol was re por ted to ha ve po tent an ti can cer ac ti vi ti es in pros ta te can cer. In this study, we se arc hed for the pos sib le syner gis tic cyto to xic/apop to tic ef fects of this com bi na ti on tre at ment in hor mo neand drug re sis tant pros ta te can cer cell li ne, DU-145 vi a in hi bi ti on of Bcl-2 pro te in. Ma te ri al and Met hods: XTT cell vi a bi lity as say was used to as sess cyto to xi city of the drugs alo ne and in com bi na ti on. For ve rif ying apop to sis, Cell De ath De tec ti on Eli sa Plus Kit and Cas pa se-Glo 3/7 as say we re used. Wes tern Blot analy sis for Bcl-2 pro te in was car ri ed out. Re sults: A no vel drug com bi na ti on of do ce ta xel and goss ypol re sul ted in a sig ni fi cant syner gis tic cyto to xic ac ti vity and apop to sis as com pa red to any sing le agent alo ne, in a do seand ti me de pen dent manner, and al so sig ni fi cantly re du ced Bcl-2 pro te in le vels in DU-145, in doses that can be used cli ni cally. Conc lu si on: Ad ding goss ypol to do ce ta xel as a com bi na ti on tre at ment in HRPC pa ti ents might be a so lu ti on for ta xa ne re sis tant pa ti ents. In hi bi ti on of Bcl-2 might be one of the un derl ying ro u tes of ac ti vity for this com bi na ti on.

türkiye klinikleri tıp bilimleri dergisi

Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol